Dynavax is developing CpG 1018 as a broad vaccine adjuvant platform. With that as the goal, the company has embarked on a strategy to establish multiple research collaborations aimed at demonstrating the capability of CpG 1018 to enhance the immune response to a variety of vaccine antigens.
Dynavax is developing plans for scale-up activities to support pandemic level of production of CpG 1018 adjuvant, as necessary, to support the company’s multiple collaborations to develop a coronavirus vaccine.
Dynavax is actively forming partnerships—already collaborating with Valneva, Sinovac, the Coalition for Epidemic Preparedness Innovations (CEPI), the University of Queensland, and Clover Biopharmaceuticals—to offer its patented CpG 1018 adjuvant, which enhances the immune system response to a coronavirus vaccine.
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships.
Hit enter to search or ESC to close